BRAF inhibitor-induced panniculitis appearance on 18F-FDG PET/CT

Stephen M. Broski, Erin K. Moran, Katrina N. Glazebrook, Mark A. Nathan

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules. These nodules may demonstrate uptake on 18F-FDG PET/CT, whichmay mimic metastatic disease in patients undergoing treatment. We present a case of BRAF inhibitor-induced panniculitis in a patient with stage IV metastatic melanoma and discuss the imaging findings on 18F-FDG PET/CT.

Original languageEnglish (US)
Pages (from-to)e149-e151
JournalClinical nuclear medicine
Volume41
Issue number3
DOIs
StatePublished - Jan 1 2016

Keywords

  • BRAF
  • FDG
  • PET/CT
  • Panniculitis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'BRAF inhibitor-induced panniculitis appearance on <sup>18</sup>F-FDG PET/CT'. Together they form a unique fingerprint.

  • Cite this